(E)-3-(prop-1-en-1-yl)-1H-pyrazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (E)-3-(prop-1-en-1-yl)-1H-pyrazole
• 英文别名: 5-[(E)-prop-1-enyl]-1H-pyrazole
• 化学式: C₆H₈N₂
• 分子量: 108.143
• InChiKey: PMCWUJVAHXMNRL-NSCUHMNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-Ethynyl-2-butenyl alcohol 在 (1,4-dimethyl-5,7-diphenyl-1,2,3,4-tetrahydro-6H-cyclopenta[b]pyrazin-6-one)ruthenium tricarbonyl complex 、 一水合肼 作用下， 以 甲苯 为溶剂， 以37%的产率得到(E)-3-(prop-1-en-1-yl)-1H-pyrazole
  参考文献：
  名称：

  从炔丙醇和肼中钌催化形成吡唑或 3-羟基腈

  摘要：

  官能化吡唑是在钌催化的级联过程中由仲丙醇和肼生成的，包括氧化还原异构化、迈克尔加成、环缩合和脱氢步骤。相同的双功能催化剂通过反马尔可夫尼科夫加氢胺化随后消除氨来介导炔丙醇叔醇与肼的转化为 3-羟基腈。

  DOI：

  10.24820/ark.5550190.p010.893

文献信息

• METHODS AND COMPOSITIONS OF SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY
  申请人：Angion Biomedica Corp.

  公开号：US20180009793A1

  公开（公告）日：2018-01-11

  The present invention provides compositions and formulations of compounds having formula (I) and pharmaceutically acceptable derivatives thereof, wherein p, R 1 , R 2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role. In addition, methods are provided for treating such diseases or diseases starting at a time after the onset of the injury, condition or disease.

  本发明提供具有公式（I）及其药学上可接受的衍生物的组合物和配方，其中p，R1，R2和B如本文中一般和在类和子类中所述，并提供其制药组合物以及使用它们治疗HGF/SF或其活性或其激动剂或拮抗剂在治疗中有治疗用途的任何损伤，疾病或疾病的方法。此外，还提供了治疗这些疾病或在损伤，疾病或疾病发病后的时间开始治疗的方法。
• Small molecule modulators of hepatocyte growth factor (scatter factor) activity
  申请人：Zembower E. David

  公开号：US20080015243A1

  公开（公告）日：2008-01-17

  The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 , R 2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role.

  本发明提供具有公式（I）的化合物及其药学上可接受的衍生物，其中R1、R2和B如本文中一般和在各类和亚类中所描述的，并且还提供了其制药组合物，以及使用它们治疗HGF/SF或其活性或其激动剂或拮抗剂在治疗中具有治疗用途的多种情况或疾病的方法。
• Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity
  申请人：Angion Biomedica Corp.

  公开号：EP2292227A2

  公开（公告）日：2011-03-09

  The present invention provides compounds having formula (I) and pharmaceutically acceptable derivatives thereof, wherein R1, R2 and B are as described generally and n classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role.

  本发明提供了具有式（I）的化合物及其药学上可接受的衍生物，其中 R1、R2 和 B 如本文中一般和 n 类及亚类所述，此外，本发明还提供了其药物组合物及其使用方法，用于治疗 HGF/SF 或其活性或其激动剂或拮抗剂具有治疗作用的多种病症或疾病中的任何一种。
• HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN FIBROTIC CONNECTIVE TISSUE DISEASES
  申请人：Paka Latha

  公开号：US20100256117A1

  公开（公告）日：2010-10-07

  Methods are provided for treating fibrotic connective tissue diseases such as scleroderma and conditions such as surgically-induced adhesions using compounds that activate the signaling pathways of hepatocyte growth factor.
• HEPATOCYTE GROWTH FACTOR PATHWAY ACTIVATORS IN DEMYELINATING DISEASES AND CENTRAL NERVOUS SYSTEM TRAUMA
  申请人：Yuzhakov Alexander

  公开号：US20110230407A1

  公开（公告）日：2011-09-22

  Methods are provided for treating and preventing demyelinating diseases including multiple sclerosis, and traumatic injury to the central nervous system including brain trauma and spinal cord injury, by administering a compound or pharmaceutical composition of the invention. Useful compounds include hepatocyte growth factor/scatter factor protein, fragments, fusion polypeptides and muteins thereof, and nucleic acid and expression vectors encoding such proteins. Other useful compounds include small molecule HGF/SF agonists and mimetics.